within Pharmacolibrary.Drugs.C_CardiovascularSystem.C02L_AntihypertensivesAndDiureticsInCombination.C02LC05_MoxonidineAndDiuretics;

model MoxonidineAndDiuretics
  extends Pharmacolibrary.Drugs.ATC.C.C02LC05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C02LC05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Moxonidine is an antihypertensive agent acting as a selective I1-imidazoline receptor agonist, reducing sympathetic nervous activity; it is often used in combination with diuretics for the treatment of hypertension. The fixed combination (C02LC05) is indicated for blood pressure management primarily in adults. The combination is approved in some countries but not all.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies reporting PK parameters for the fixed combination of moxonidine with diuretics (ATC C02LC05) were found as of 2024. The following values are estimated based on published PK data for moxonidine monotherapy in healthy adults (oral dosing), as diuretics typically do not markedly alter moxonidine's PK profile.</p><h4>References</h4><ol><li><p>Prichard, BN, &amp; Graham, BR (1997). The use of moxonidine in the treatment of hypertension. <i>Journal of hypertension. Supplement : official journal of the International Society of Hypertension</i> 15(1) S47–S55. DOI:<a href=\"https://doi.org/10.1097/00004872-199715011-00007\">10.1097/00004872-199715011-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9050986/\">https://pubmed.ncbi.nlm.nih.gov/9050986</a></p></li><li><p>Prichard, BN, et al., &amp; Graham, BR (1997). Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. <i>Journal of human hypertension</i> 11 Suppl 1 S29–S45. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9321737/\">https://pubmed.ncbi.nlm.nih.gov/9321737</a></p></li><li><p>Prichard, BN, &amp; Graham, BR (2000). I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. <i>Drugs &amp; aging</i> 17(2) 133–159. DOI:<a href=\"https://doi.org/10.2165/00002512-200017020-00005\">10.2165/00002512-200017020-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10984201/\">https://pubmed.ncbi.nlm.nih.gov/10984201</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MoxonidineAndDiuretics;
